---
title: "Stocks in Play: Satellos Bioscience Inc."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300050214.md"
description: "11:06 AM EST - Satellos Bioscience Inc. : Announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026. Satellos Bioscience Inc. shares T.MSCL are trading down $0.04 at $12.13."
datetime: "2026-09-24T15:10:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300050214.md)
  - [en](https://longbridge.com/en/news/300050214.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300050214.md)
generator: "portal-rs"
---

# Stocks in Play: Satellos Bioscience Inc.

**11:06 AM EST - Satellos Bioscience Inc. :** Announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026. Satellos Bioscience Inc. shares T.MSCL are trading **down $0.04** at $12.13.

### Related Stocks

- [MSLE.US](https://longbridge.com/en/quote/MSLE.US.md)

## Related News & Research

- [Satellos Changes Primary Endpoint to MRI-Measured Fat Fraction in Phase 2 Duchenne Trial After FDA Feedback](https://longbridge.com/en/news/304633307.md)
- [Insider Stock Buyers At Satellos Bioscience Recouped Some Losses This Week](https://longbridge.com/en/news/304839177.md)
- [The Buffett Indicator Is Flashing Red. These 3 Dividend Stocks Could Be Safe Havens.](https://longbridge.com/en/news/304985751.md)
- [‘Same Old Story,’ Says Investor About Rocket Lab Stock](https://longbridge.com/en/news/305045505.md)
- [What's Going On With Trade Desk Stock Tuesday?](https://longbridge.com/en/news/304999508.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**